Zhejiang Weikang Pharmaceutical Co., Ltd. announced its product, Ganmao Qingre Granules, was selected in the National Chinese Patent Medicine Group Centralized Procurement. This selection is expected to expand sales and market share, positively impacting future performance. However, the final contract signing and sales are subject to market and policy uncertainties.
Summary generated by AI · Always verify with source document
Securities Code: 300878 Securities Abbreviation: Weikang Pharmaceutical Announcement No.: 2026-030 Zhejiang Weikang Pharmaceutical Co., Ltd. Announcement on Company Product Selected in National Chinese Patent Medicine Group Centralized Procurement
The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.